Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: A six-year clinical experience

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2733-2742

  Riva, Pietro ^a   Franceschi, Giancarlo ^a   Arista, Agostino ^a   Frattarelli, Massimo ^a   Riva, Nada ^a   Cremonini, Anna Maria ^a   Giuliani, Giuliano ^a   Casi, Michela ^a  

^a BUFALINI HOSPITAL   (Italy)

Author keywords

Intralesional radioimmunotherapy; Malignant glioma; Monoclonal antibody

Indexed keywords

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY BC 2 I 131; MONOCLONAL ANTIBODY BC 4 I 131; MONOCLONAL ANTIBODY I 131; TENASCIN; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESPONSE; GLIOBLASTOMA; HEADACHE; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

EID: 0031456943     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2733::aid-cncr53>3.0.co;2-9     Document Type: Conference Paper

References (33)

1. Ransonhoff J, Kelly P, Laws E. The role of intracranial surgery for the treatment of malignant gliomas. Semin Oncol 1986;13:27-37.
2. Shapiro WR, Shapiro JR. Principles of brain tumor chemotherapy. Semin Oncol 1986;13:56-69.
3. Kida Y, Mori Y, Hattori T, Kobayasi T. Interstitial hypertermia of malignant glioma with implant heating system. No Shinkei Geka 1990;18:1007-14.
4. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin-2 therapy of human glioma. J Neurosurg 1989;70:175-82.
5. Boiardi A, Pozzi A, Salmaggi A, Solari A, Broggi G, Silvani A. Interstitial chemotherapy additionally delivered to systemic treatment improves the outcome of glioblastoma (GBM) patients. J Neurooncol 1996;30:108.
6. Florell RC, Macdonald DR, Irish WD, Bernstein M, Leibel SA, Gutin PH, et al. Selection bias, survival, and brachytherapy for glioma. J Neurosurg 1992;76:179-83.
7. Ostertag ChB. Brachytherapy: interstitial implant radiosurgery. Acta Neurochir Suppl (Wein) 1992;58:79-84.
8. Sturm V, Schlegel W, Pastyr O, Treuer H, Voges J, Muller RP, et al. Linear-accelerator radiosurgery. Acta Neurochir Suppl (Wein) 1992;58:85-8.
9. Goldenberg DM, Griffith GL. Radioimmunotherapy of cancer: arming the missiles. J Nucl Med 1992;33:1110-2.
10. McDermott MW, Gutin PH, Larson DA, Sneed PK. Interstitial brachytherapy. Neurosurg Clin N Am 1996;1:801-24.
11. 131I monoclonal antibodies in treating neural tumors. In: Vaeth IM, Meuer IL, editors. The present and future role of monoclonal antibodies in the management of cancer. Front Radiat Ther Oncol. Volume 24. Basel:Karger, 1990:166-81.
12. Pizer B, Papanastassiou V, Hancock J, Cassano W, Coakam HB, Kemshead JT. A pilot study of monoclonal targeted radiotherapy in the treatment of central nervous system leukaemia in children. Br J Haematol 1991;77:466-72.
13. Pizer BL, Kemshead JT. The potential of targeted radiotherapy in the treatment of central nervous system leukemia. Leuk Lymphoma 1994;15:281-9.
14. 90Yttrium labelled monoclonal antibody MUC 2-63. In: Epenetos A, editor. Monoclonal antibodies: applications in clinical oncology. London: Chapman and Hall Medica, 1992:17-25.
15. Papanastassiou V, Pizer BL, Coakam HB, Bullimore J, Zananiri T, Kemshead JT. Treatment of recurrent and cystic malignant glioma by a single intracavitary injection of I-131 monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br J Cancer 1993;67:144-151.
16. 131I labelled BC-2 monoclonal antibody: clinical experience in 11 patients. In: Hofer R, Bergmenn H, Sinzinger H, editors. Radioactive isotopes in clinical medicine and research. Stuttgart: Scattauer; 1992:40-4.
17. Siri A, Carnemolla B, Saginati M, Leprini A, Casari G, Baralle F, et al. Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclanal antibodies. Nuclear Acids Res 1991;19:525-31.
18. Natali PG, Nicotra MR, Bigotti A, Borri C, Castellani P, Risso AM, et al. Comparative analysis of the expression of the extracellular matrix protein tenascin in normal and human fetal, adult and tumor tissues. Int J Cancer 1991;47:811-6.
19. Higuchi M, Ohnishi T, Arita N, Hiraga S, Hayakawaka T. Expression of tenascin in human gliomas: its relation to histological malignancy, tumor differentiation and angiogenesis. Acta Neuropathol 1993;85:481-7.
20. Lindmo T, Bunn PA. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabelling. Methods Enzymol 1986;121:678-91.
21. Leibel SA, Scott CB, Loeffler JS. Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Semin Oncol 1994;21:198-219.
22. Riva P, Arista A, Tison V, Sturiale C, Franceschi G, Spinelli A, et al. Intralesional radioimmunotherapy of malignant glioma: an effective treatment in recurrent tumors. Cancer 1994;73(Suppl):1076-82.
23. Zalutsky MR, Moseley RP, Coakham HB, Coleman RE, Bigner DD. Pharmacokinetics and tumor localisation of I-131 labelled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 1989;49:2807-13.
24. Mird pamphlet No. 11. New York: Society of Nuclear Medicine, 1985.
25. Loevinger R, Berman M. A schema for absorbed dose calculation for biologically distributed radionuclides. MIRD pamphlet n.1. J Nucl Med 9(suppl. 1), 7.
26. Riva P, Arista A, Sturiale C, Moscatelli G, Tison V, Mariani M, et al. Treatment of intracranial human glioblastoma by direct intratumoral administration of I-131 labelled antitenascin monoclonal antibody BC-2. Int J Cancer 1992;51:7-13.
27. 131I radiolabeled monoclonal antibodies. In: Goldenberg DM, editor. Cancer therapy with radiolabeled antibodies. Boca Raton: CRC Press, 1994:203-16.
28. Sturiale C, Arista A, Lazzari S, Frattarelli M, Donati R, Sarti G, et al. Intralesional radioimmunotherapy of malignant gliomas: clinical experiences with recurrent and primary tumors. Tumor Targeting 1995; 1:163-76.
29. Chittenden S, Thomas R, Hall A, Smith T, Flux G, Brada M. Dosimetry of intralesional I-131 monoclonal antibody (Mab) therapy in patients with recurrent high grade malignant glioma. In: Bergmenn H, Sinzinger H, editors. Radioactive isotopes in clinical medicine and research. Advances in pharmacological sciences. Basel: Birkauser, Verlag, 1995:29-34.
30. Dillman RO. Human antimouse and antiglobulin responses to monoclonal antibodies. Antibody Immunoconj Radiopharm 1990;3:1-8.
31. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Stat Assoc 1958;53:457-81.
32. Shapiro WR. Therapy of adult malignant brain tumors: what have the clinical trials taught us? Semin Oncol 1986;13:38-45.
33. World Health Organization handbook for reporting results of cancer treatments. Offsets Publication No. 40, 1979. Geneva: World Health Organization, 1979.